Abstract:Abstract Precision oncology hinges on accurate prediction of patient-specific treatment response from tumor molecular inputs. While deep learning (DL) models achieve state-of-the-art response prediction in cell lines, existing methods do not readily translate to the clinic where training data is limited. Here, we have developed and validated ScreenDL, a novel DL framework designed explicitly for use in clinical precision oncology applications. The underlying architecture of ScreenDL consists of two fully connected branches dedicated to learning rich embeddings of a drug’s chemical structure and a tumor’s transcriptomic profile respectively. These tumor omic and drug molecular embeddings are fed into a shared response prediction subnetwork which outputs predicted ln(IC50) values. The ScreenDL training schema incorporates three phases, each designed to improve clinical response prediction: (1) an initial pretraining phase leverages large-scale cell line pharmacogenomic datasets to extract patterns/relationships linking tumor omics and drug response; (2) subsequent transfer learning integrates pharmacogenomic data from patient-derived models of cancer, adapting the pretrained model to a more patient-relevant context; (3) patient-level omics and drug screening data (e.g., from matched patient-derived organoid (PDO) models) is integrated through patient-specific fine-tuning, generating a patient-specific response prediction model. Importantly, biomaterial from surgical tumor resection is often available for organoid establishment and patient-specific drug screening in practical clinical scenarios. To assess the utility of our ScreenDL framework for clinical response prediction, we applied ScreenDL to predict treatment response in 50 advanced/metastatic triple negative breast cancer (TNBC) patient-derived xenograft models (PDX). We leveraged tumor omics profiles for each PDX and drug screening data from matched PDX-derived organoids (PDxOs), mirroring the combination of patient-level tumor omic characterization and functional drug screening in matched PDOs, a protocol currently being piloted in Functional Precision Oncology trials at the University of Utah Huntsman Cancer Institute. After cell line pretraining, ScreenDL achieves a modest median Pearson correlation per drug of 0.15 relative to 0.03 for the leading compared model. However, transfer learning and subsequent PDX-specific fine-tuning significantly improve performance, producing median Pearson correlations per drug of 0.39 and 0.51, respectively. These results demonstrate the ability of our ScreenDL framework to dramatically improve response prediction in clinically relevant domains, bringing DL-based precision treatment selection closer to clinical application. Citation Format: Casey Sederman, Tonya Di Sera, Yi Qiao, Xiaomeng Huang, Bryan E. Welm, Alana L. Welm, Gabor Marth. ScreenDL: A transfer learning framework integrating tumor omics and functional drug screening for personalized clinical drug response prediction [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 907.

Deep Transfer Learning of Drug Responses by Integrating Bulk and Single-cell RNA-seq data

Enabling Single‐Cell Drug Response Annotations from Bulk RNA‐Seq Using SCAD

Single-Cell Techniques and Deep Learning in Predicting Drug Response.

TransCell: In silico Characterization of Genomic Landscape and Cellular Responses by Deep Transfer Learning

MetaSCDrug: Meta-Transfer Learning for Single-Cell-Level Drug Response Prediction from Transcriptome and Molecular Representations

Identification of cell types, states and programs by learning gene set representations

DeepDRK: a deep learning framework for drug repurposing through kernel-based multi-omics integration

Identifying drug-resistant individual cells within tumors by semi-supervised transfer learning from bulk to single-cell transcriptome

DeepDSC: A Deep Learning Method to Predict Drug Sensitivity of Cancer Cell Lines

TransCDR: a deep learning model for enhancing the generalizability of cancer drug response prediction through transfer learning and multimodal data fusion for drug representation

DeepFusionCDR: Employing Multi-Omics Integration and Molecule-Specific Transformers for Enhanced Prediction of Cancer Drug Responses

scDR: Predicting Drug Response at Single-Cell Resolution

Pan-Cancer Drug Sensitivity Prediction from Gene Expression using Deep Learning

DELFOS-drug efficacy leveraging forked and specialized networks-benchmarking scRNA-seq data in multi-omics-based prediction of cancer sensitivity

Trends and Potential of Machine Learning and Deep Learning in Drug Study at Single-Cell Level

Deep learning and multi-omics approach to predict drug responses in cancer

SCREP: Towards Single-Cell Drug Response Prediction by Pharmacogenomic Embedding Enhanced Meta-Pretraining and Few-Shot Transfer Learning

MMDRP: drug response prediction and biomarker discovery using multi-modal deep learning

DeepCDR: a Hybrid Graph Convolutional Network for Predicting Cancer Drug Response

Decoding Drug Response with Structurized Gridding Map-based Cell Representation.

Abstract 907: ScreenDL: A transfer learning framework integrating tumor omics and functional drug screening for personalized clinical drug response prediction